Spots Global Cancer Trial Database for Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Official Title: A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Study ID: NCT05374590
Conditions
Interventions
Study Description
Brief Summary: The purpose of this trial is to evaluate the long-term safety of efgartigimod IV and efgartigimod PH20 SC administered to participants with gMG in the antecedent studies, ARGX-113-2006 and ARGX-113-2207, respectively.
Detailed Description:
Keywords
Eligibility
Minimum Age: 2 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
University of Virginia, Charlottesville, Virginia, United States
UZ Antwerpen, Antwerp, , Belgium
Leiden University Medical Center, Leiden, , Netherlands
Wielospecjalistyczna Poradnia Lekarska Synapsis, Katowice, , Poland
Uniwersyteckie Centrum Kliniczne WUM, Centralny Szpital Kliniczny, Warszawa, , Poland
Oxford University hospitals NHS Foundation Trust-Oxford Children's Hospital, Oxford, , United Kingdom
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
